To include your compound in the COVID-19 Resource Center, submit it here.

Triangle, Abbott end anti-infective deal

VIRS and ABT mutually ended their 1999 deal to develop VIRS's anti-infectives (see BioCentury, June 07 1999, A7). As a result, VIRS reacquired

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE